NCT06720766 Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
| NCT ID | NCT06720766 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Third People's Hospital of Chengdu |
| Condition | Fatty Liver Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2023-10-24 |
| Primary Completion | 2025-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2023-10-24 with a primary completion date of 2025-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity. The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18 years or older who provided written informed consent 2. Patients who schedule to undergo bariatric surgery and a liver biopsy (LB) for the investigation of suspected MASLD 3. Patients who schedule to undergo FibroScan examination Exclusion Criteria: 1. Patients with ascites or pregnant women 2. Patients with any active implantable medical device (such as a pacemaker or defibrillator) 3. Patients who have undergone liver transplantation 4. Patients with cardiac failure and/or significant valvular disease 5. Patients with haemochromatosis 6. Patients who have refused to undergo LB or blood tests 7. Patients with a confirmed diagnosis of active malignancy, or other terminal disease 8. Patients participating in another clinical trial within the preceding 30 days
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06720766 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Fatty Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06720766 currently recruiting?
Yes, NCT06720766 is actively recruiting participants. Contact the research team at peisenguo@163.com for enrollment information.
Where is the NCT06720766 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT06720766 clinical trial?
NCT06720766 is sponsored by The Third People's Hospital of Chengdu. The trial plans to enroll 600 participants.